The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Imatinib compared with chemotherapy as front‐line treatment of elderly patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ALL)
Open accessAbstract
BACKGROUND: Elderly patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ALL) have a poor prognosis, with a low complete remission (CR) rate, high induction mortality, and short remission duration. Imatinib (IM) has a favorable toxicity profile but limited antileukemic activity in advanced Ph+ALL. Imatinib in combination with intensive chemotherapy has yielded promising results as front‐line therapy, but its value as monotherapy in newly diagnosed Ph+ALL is not known. METHODS: Patients with de novo Ph+ALL were randomly assigned to induction therapy with either imatinib (Ind IM) or multiagent, age‐adapted chemotherapy (Ind chemo). Imatinib was subsequently coadministered with consolidation chemotherapy. RESULTS: In all, 55 patients (median age, 68 years) were enrolled. The overall CR rate was 96.3% in patients randomly assigned to Ind IM and 50% in patients allocated to Ind chemo (P = .0001). Nine patients (34.6%) were refractory and 2 patients died during Ind chemo; none failed imatinib induction. Severe adverse events were significantly more frequent during Ind chemo (90% vs 39%; P = .005). The estimated overall survival (OS) of all patients was 42% ± 8% at 24 months, with no significant difference between the 2 cohorts. Median disease‐free survival was significantly longer in the 43% of patients (21 of 49 evaluable) in whom BCR‐ABL transcripts became undetectable (18.3 months vs 7.2 months; P = .002). CONCLUSIONS: In elderly patients with de novo Ph+ALL, imatinib induction results in a significantly higher CR rate and lower toxicity than induction chemotherapy. With subsequent combined imatinib and chemotherapy consolidation, this initial benefit does not translate into improved survival compared with chemotherapy induction. Cancer 2007. © 2007 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Cited by
Modern Therapy of Acute Lymphoblastic Leukemia
Bassan, R., & Hoelzer, D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.1382 · Cited by 485
Self-citationFoà, R., Vitale, A., Vignetti, M., Meloni, G., Guarini, A., De Propris, M. S., Elia, L., Paoloni, F., Fazi, P., Cimino, G., et al. (2011) · Blood · doi:10.1182/blood-2011-05-351403 · Cited by 462
Ravandi, F., O'Brien, S., Thomas, D., Faderl, S., Jones, D., Garris, R., Dara, S., Jorgensen, J., Kebriaei, P., Champlin, R., et al. (2010) · Blood · doi:10.1182/blood-2009-12-261586 · Cited by 348
Biondi, A., Schrappe, M., De Lorenzo, P., Castor, A., Lucchini, G., Gandemer, V., Pieters, R., Stary, J., Escherich, G., Campbell, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70377-7 · Cited by 330
Fielding, A. K., Rowe, J. M., Richards, S. M., Buck, G., Moorman, A. V., Durrant, I. J., Marks, D. I., McMillan, A. K., Litzow, M. R., Lazarus, H. M., et al. (2009) · Blood · doi:10.1182/blood-2009-01-199380 · Cited by 291
Metadata
- Authors
- Ottmann, O. G., Wassmann, B., Pfeifer, H., Giagounidis, A., Stelljes, M., Dührsen, U., Schmalzing, M., Wunderle, L., Binckebanck, A., & Hoelzer, D.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2007-04-11
- Volume
- 109
- Issue
- 10
- Pages
- 2068-2076
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2089360398
- Cited by
- 250
- References
- 1
- FWCI
- 22.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Imatinib compared with chemotherapy as front‐line treatment of elderly patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ALL). https://app.cochat.ai/papers/10.1002/cncr.22631
- The paper
- Ottmann, O. G., Wassmann, B., Pfeifer, H., Giagounidis, A., Stelljes, M., Dührsen, U., Schmalzing, M., Wunderle, L., Binckebanck, A., & Hoelzer, D. (2007). Imatinib compared with chemotherapy as front‐line treatment of elderly patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ALL). Cancer. https://doi.org/10.1002/cncr.22631
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.